Cargando…

Pretreatment neutrophil‐lymphocyte ratio is not a significant prognostic factor in epidermal growth factor receptor‐mutant non‐small cell lung cancer patients treated with tyrosine kinase inhibitors

BACKGROUND: The neutrophil‐lymphocyte ratio (NLR) is a marker of poor prognosis in lung cancer patients. However, previous data have been based on an heterogeneous population of lung cancer patients and various treatments. In this study, we evaluate the prognostic value of NLR in an homogeneous popu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sim, Sung Hoon, Beom, Seung‐Hoon, Ahn, Yong‐Oon, Keam, Bhumsuk, Kim, Tae Min, Lee, Se‐Hoon, Kim, Dong‐Wan, Heo, Dae Seog
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4773306/ https://www.ncbi.nlm.nih.gov/pubmed/27042217 http://dx.doi.org/10.1111/1759-7714.12304

Ejemplares similares

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Keam, Bhumsuk, et al.
Publicado: (2014)

Intratumoral heterogeneity characterized by pretreatment PET in non-small cell lung cancer patients predicts progression-free survival on EGFR tyrosine kinase inhibitor
por: Park, Sehhoon, et al.
Publicado: (2018)

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations
por: Park, Sehhoon, et al.
Publicado: (2016)

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations
por: Park, Sehhoon, et al.
Publicado: (2015)

Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients
por: Beom, Seung-Hoon, et al.
Publicado: (2016)

Cancer Treatment near the End-of-Life Becomes More Aggressive: Changes in Trend during 10 Years at a Single Institute
por: Choi, Younak, et al.
Publicado: (2015)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

The Impact of Molecularly Targeted Treatment on Direct Medical Costs in Patients with Advanced Non-small Cell Lung Cancer
por: Lee, June-Koo, et al.
Publicado: (2015)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2017)

Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis
por: Cha, Soojin, et al.
Publicado: (2016)

Reduced Dose Intensities of Doxorubicin in Elderly Patients with DLBCL in Rituximab Era
por: Ha, Hyerim, et al.
Publicado: (2016)

Targeting CD73 to Overcomes Resistance to First-Generation EGFR Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
por: Kim, Miso, et al.
Publicado: (2023)

The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
por: Choi, Ji Young, et al.
Publicado: (2019)

How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution
por: Keam, Bhumsuk, et al.
Publicado: (2013)

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
por: Kim, Hyungjin, et al.
Publicado: (2017)

Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
por: Kim, Miso, et al.
Publicado: (2015)

Failure patterns of cervical lymph nodes in metastases of unknown origin according to target volume
por: Kim, Dong-Yun, et al.
Publicado: (2020)

Treatment strategy for papillary renal cell carcinoma type 2: a case series of seven patients treated based on next generation sequencing data
por: Kim, Ji-Yeon, et al.
Publicado: (2020)

The Prognostic Value of Albumin-to-Alkaline Phosphatase Ratio before Radical Radiotherapy in Patients with Non-metastatic Nasopharyngeal Carcinoma: A Propensity Score Matching Analysis
por: Kim, Jae Sik, et al.
Publicado: (2019)

Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma
por: Kang, Minsu, et al.
Publicado: (2021)

The Effect of Hospice Consultation on Aggressive Treatment of Lung Cancer
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Generalization and representativeness of phase III immune checkpoint blockade trials in non‐small cell lung cancer
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
por: Oh, So Yeon, et al.
Publicado: (2021)

Hospice-Palliative Medicine as a Model of Value-Based Healthcare
por: Heo, Dae Seog, et al.
Publicado: (2022)

Definitive Radiotherapy versus Postoperative Radiotherapy for Tonsil Cancer
por: Koo, Tae Ryool, et al.
Publicado: (2012)

Molecular Basis of Drug Resistance: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Anaplastic Lymphoma Kinase Inhibitors
por: Yang, Sei-Hoon
Publicado: (2013)

Clinical factors affecting progression-free survival with crizotinib in ALK-positive non-small cell lung cancer
por: Ock, Chan-Young, et al.
Publicado: (2019)

Novel systemic therapies in the management of tyrosine kinase inhibitor-pretreated patients with epidermal growth factor receptor-mutant non-small-cell lung cancer
por: Li, Yang-Si, et al.
Publicado: (2023)

Problems Related to the Act on Decisions on Life-Sustaining Treatment and Directions for Improvement
por: Heo, Dae Seog, et al.
Publicado: (2022)

Optimal timing for salvage surgery after definitive radiotherapy in hypopharyngeal cancer
por: Chun, Seok-Joo, et al.
Publicado: (2018)

Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017)

Difficulties Doctors Experience during Life-Sustaining Treatment Discussion after Enactment of the Life-Sustaining Treatment Decisions Act: A Cross-Sectional Study
por: Yoo, Shin Hye, et al.
Publicado: (2021)

VEGF and Ki-67 Overexpression in Predicting Poor Overall Survival in Adenoid Cystic Carcinoma
por: Park, Seongyeol, et al.
Publicado: (2016)

The antitumor activity of a novel GCN2 inhibitor in head and neck squamous cell carcinoma cell lines
por: Lee, Jeongjae, et al.
Publicado: (2022)

Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity
por: Yoo, Shin Hye, et al.
Publicado: (2018)

Impact of clinicopathologic features on leptomeningeal metastasis from lung adenocarcinoma and treatment efficacy with epidermal growth factor receptor tyrosine kinase inhibitor
por: Kwon, Byoung Soo, et al.
Publicado: (2020)

Use of high‐flow nasal cannula oxygen therapy for patients with terminal cancer at the end of life
por: Kim, Jung Sun, et al.
Publicado: (2023)

Epidermal Growth Factor Receptor Mutations and the Clinical Outcome in Male Smokers with Squamous Cell Carcinoma of Lung
por: Park, Se Hoon, et al.
Publicado: (2009)

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker
por: Keam, Bhumsuk, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_0kkr8lhrr3ampddnh1dkuiv3db